Galafold, migalastat (AT1001) (formerly Amigal)

Collapse Summary General Information
Company Amicus Therapeutics Inc.
DescriptionSmall molecule stabilizer of alpha galactosidase A
Molecular Target Alpha galactosidase A
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationFabry's disease
Indication DetailsTreat Fabry's disease
Regulatory Designation U.S. - Fast Track (Treat Fabry's disease);
EU - Accelerated Assessment (Treat Fabry's disease);
EU - Orphan Drug (Treat Fabry's disease);
Japan - Orphan Drug (Treat Fabry's disease)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$50.0M

0

$50.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/29/2010

$50.0M

Undisclosed

$50.0M

Get a free BioCentury trial today